KBIOHealth and Ibcell Partner to Advance iPSC-Based Medical Product Development

Osong Advanced Medical Industry Promotion Foundation (KBIOHealth) and Ibcell have entered into a collaborative agreement to accelerate the development of innovative medical products utilizing induced pluripotent stem cell (iPSC) technology. The partnership, formalized through a memorandum of understanding (MOU) on February 23, 2026, aims to address key challenges in translating iPSC research into clinical applications.

Key Areas of Collaboration

The agreement outlines several key areas of cooperation between KBIOHealth and Ibcell:

• Joint Research: Conducting collaborative research to develop advanced medical products based on iPSCs and organoids.
• Non-Clinical Evaluation: Jointly developing non-clinical evaluation technologies utilizing advanced alternative testing methods and space environment simulations.
• Clinical Translation: Establishing joint clinical translation strategies through the exchange of key technologies and information related to iPSC-based advanced medical products and non-clinical evaluations.

Statements from Leadership

Lee Myung-soo, Chairman of KBIOHealth, stated that the agreement will enhance the research competitiveness of South Korea’s advanced bio and regenerative medicine fields by establishing a joint research and non-clinical evaluation system for iPSC-based product development. KBIOHealth will continue to expand practical research and commercialization support for companies by linking infrastructure and expertise.

Joo Ji-hyun, CEO of Ibcell, noted that combining Ibcell’s iPSC and organoid-based core technology with KBIOHealth’s non-clinical infrastructure will significantly accelerate the commercialization of cutting-edge medical product development. She anticipates the agreement will secure global competitiveness by generating practical research results in Ibcell’s key technology areas, including alternative testing methods and space medical research.

About KBIOHealth and Ibcell

KBIOHealth (Osong Advanced Medical Industry Promotion Foundation) is dedicated to supporting the growth of the biomedical industry in South Korea. KBIOHealth focuses on overcoming obstacles to R&D commercialization, such as the “Death Valley of Value Innovation” and regulatory hurdles, through sustained investment and infrastructure support.

Ibcell specializes in iPSC and organoid-based technologies. Osong Bio Promotion Foundation supports companies like Ibcell and promotes the K-bio industry globally.

Looking Ahead

This collaboration between KBIOHealth and Ibcell represents a significant step towards advancing iPSC-based medical product development in South Korea. By combining expertise and resources, the two organizations aim to accelerate innovation and bring new therapies to patients.